NanoViricides Announces $6 Million Fundraising Through Direct Offering and Private Placement

NanoViricides, Inc., based in Shelton, Connecticut, has secured a securities purchase agreement with a single healthcare institutional investor. This agreement involves the sale of 3,571,429 shares of common stock at $1.68 per share, amounting to approximately $6 million in gross proceeds. The transaction is expected to close on or around November 12, 2025, subject to customary conditions. The proceeds will primarily support working capital and general corporate purposes.

In a concurrent private placement, NanoViricides will issue Series A and Series B warrants, each allowing the purchase of up to 3,571,429 shares. The Series A Warrants are priced at $1.75 per share, while Series B Warrants come at a 20% premium to the stock's closing price, with an exercise price of $2.00.